8-K current report · filed Aug 28, 2026

Spero Therapeutics Inc (SPRO) 8-K Current Report: August 28, 2026

Item 1.01Item 8.01SPRO overview

Short answer

Spero Therapeutics Inc (SPRO) filed an 8-K current report with the SEC on August 28, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 8.01 (Other Events). Spero authorized an at-the-market equity offering of up to $100 million through Jefferies.

Spero Therapeutics Inc 8-K event analysis

AI summary of each reported item and its exhibits

Item 1.01 · Entry into a Material Definitive Agreement

  • Spero authorized an at-the-market equity offering of up to $100 million through Jefferies
  • Sales cannot begin until the $300 million universal shelf registration becomes effective
  • Potential proceeds provide financing flexibility, but future share issuance would dilute existing shareholders
  • Jefferies compensation up to 3.0% of gross proceeds, reducing net capital raised

Item 8.01 · Other Events

  • Cantor ATM agreement terminated effective August 28, 2026
  • $75 million equity issuance capacity eliminated under the Cantor Prospectus
  • No termination penalties incurred, limiting immediate cash costs
  • No shares sold through the facility during fiscal years 2025 or 2024
  • Future common-stock sales through this ATM offering are no longer available

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Spero Therapeutics Inc 8-K filings

Get the next SPRO 8-K as it lands

Follow SPRO for push alerts, or ask the research agent what this filing means.